Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States: Report from the National LymphoCare Study

Chadi Nabhan, Michelle Byrtek, Michael D. Taylor, Jonathan W. Friedberg, James R. Cerhan, John D. Hainsworth, Thomas P Miller, Jamie Hirata, Brian K. Link, Christopher R. Flowers

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

BACKGROUND: Racial differences in follicular lymphoma (FL) in the United States have not been investigated. METHODS: The National LymphoCare Study is a multicenter, longitudinal, observational cohort study collecting data on treatment patterns and outcomes for patients with newly diagnosed FL in the United States between 2004 and 2007 without any predefined, study-specific intervention. The authors investigated differences between white (W) patients, African American (AA) patients, and Hispanic (H) patients. RESULTS: Among 2744 enrolled patients, there were 95 (3%) AA patients, 125 (5%) H patients, and 2476 (90%) W patients. Compared with W patients, more AA and H patients were diagnosed at age <45 years (P <.0001). H patients more commonly were diagnosed with grade 3 FL compared with AA and W patients (29%, 13%, and 18%, respectively; P =.019) and more commonly received rituximab plus chemotherapy as initial therapy compared with W patients (66% vs 50%; P =.036), while AA patients less commonly received anthracyclines (49% vs 64% in W patients; P =.027). H and AA patients who received rituximab plus chemotherapy were less likely than W patients to receive maintenance rituximab (27% vs 31% vs 40%, respectively; P =.031). At a median follow-up of 52 months, progression-free survival was similar between AA and W patients but was longer in H patients, and there was no difference in overall survival. CONCLUSIONS: In the largest prospective cohort to date of AA and H patients with FL in the United States, AA and H patients were younger at presentation. Although racial differences in treatment patterns for FL were noted, additional follow-up is needed to determine the impact of these differences on survival.

Original languageEnglish (US)
Pages (from-to)4842-4850
Number of pages9
JournalCancer
Volume118
Issue number19
DOIs
StatePublished - Oct 1 2012

Fingerprint

Follicular Lymphoma
Non-Hodgkin's Lymphoma
African Americans
Drug Therapy

Keywords

  • African Americans
  • follicular lymphoma
  • Hispanics
  • non-Hodgkin lymphoma
  • racial disparities

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Nabhan, C., Byrtek, M., Taylor, M. D., Friedberg, J. W., Cerhan, J. R., Hainsworth, J. D., ... Flowers, C. R. (2012). Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States: Report from the National LymphoCare Study. Cancer, 118(19), 4842-4850. https://doi.org/10.1002/cncr.27513

Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States : Report from the National LymphoCare Study. / Nabhan, Chadi; Byrtek, Michelle; Taylor, Michael D.; Friedberg, Jonathan W.; Cerhan, James R.; Hainsworth, John D.; Miller, Thomas P; Hirata, Jamie; Link, Brian K.; Flowers, Christopher R.

In: Cancer, Vol. 118, No. 19, 01.10.2012, p. 4842-4850.

Research output: Contribution to journalArticle

Nabhan, C, Byrtek, M, Taylor, MD, Friedberg, JW, Cerhan, JR, Hainsworth, JD, Miller, TP, Hirata, J, Link, BK & Flowers, CR 2012, 'Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States: Report from the National LymphoCare Study', Cancer, vol. 118, no. 19, pp. 4842-4850. https://doi.org/10.1002/cncr.27513
Nabhan, Chadi ; Byrtek, Michelle ; Taylor, Michael D. ; Friedberg, Jonathan W. ; Cerhan, James R. ; Hainsworth, John D. ; Miller, Thomas P ; Hirata, Jamie ; Link, Brian K. ; Flowers, Christopher R. / Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States : Report from the National LymphoCare Study. In: Cancer. 2012 ; Vol. 118, No. 19. pp. 4842-4850.
@article{cf86bf957a51472abd24a04d01f51b0a,
title = "Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States: Report from the National LymphoCare Study",
abstract = "BACKGROUND: Racial differences in follicular lymphoma (FL) in the United States have not been investigated. METHODS: The National LymphoCare Study is a multicenter, longitudinal, observational cohort study collecting data on treatment patterns and outcomes for patients with newly diagnosed FL in the United States between 2004 and 2007 without any predefined, study-specific intervention. The authors investigated differences between white (W) patients, African American (AA) patients, and Hispanic (H) patients. RESULTS: Among 2744 enrolled patients, there were 95 (3{\%}) AA patients, 125 (5{\%}) H patients, and 2476 (90{\%}) W patients. Compared with W patients, more AA and H patients were diagnosed at age <45 years (P <.0001). H patients more commonly were diagnosed with grade 3 FL compared with AA and W patients (29{\%}, 13{\%}, and 18{\%}, respectively; P =.019) and more commonly received rituximab plus chemotherapy as initial therapy compared with W patients (66{\%} vs 50{\%}; P =.036), while AA patients less commonly received anthracyclines (49{\%} vs 64{\%} in W patients; P =.027). H and AA patients who received rituximab plus chemotherapy were less likely than W patients to receive maintenance rituximab (27{\%} vs 31{\%} vs 40{\%}, respectively; P =.031). At a median follow-up of 52 months, progression-free survival was similar between AA and W patients but was longer in H patients, and there was no difference in overall survival. CONCLUSIONS: In the largest prospective cohort to date of AA and H patients with FL in the United States, AA and H patients were younger at presentation. Although racial differences in treatment patterns for FL were noted, additional follow-up is needed to determine the impact of these differences on survival.",
keywords = "African Americans, follicular lymphoma, Hispanics, non-Hodgkin lymphoma, racial disparities",
author = "Chadi Nabhan and Michelle Byrtek and Taylor, {Michael D.} and Friedberg, {Jonathan W.} and Cerhan, {James R.} and Hainsworth, {John D.} and Miller, {Thomas P} and Jamie Hirata and Link, {Brian K.} and Flowers, {Christopher R.}",
year = "2012",
month = "10",
day = "1",
doi = "10.1002/cncr.27513",
language = "English (US)",
volume = "118",
pages = "4842--4850",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "19",

}

TY - JOUR

T1 - Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States

T2 - Report from the National LymphoCare Study

AU - Nabhan, Chadi

AU - Byrtek, Michelle

AU - Taylor, Michael D.

AU - Friedberg, Jonathan W.

AU - Cerhan, James R.

AU - Hainsworth, John D.

AU - Miller, Thomas P

AU - Hirata, Jamie

AU - Link, Brian K.

AU - Flowers, Christopher R.

PY - 2012/10/1

Y1 - 2012/10/1

N2 - BACKGROUND: Racial differences in follicular lymphoma (FL) in the United States have not been investigated. METHODS: The National LymphoCare Study is a multicenter, longitudinal, observational cohort study collecting data on treatment patterns and outcomes for patients with newly diagnosed FL in the United States between 2004 and 2007 without any predefined, study-specific intervention. The authors investigated differences between white (W) patients, African American (AA) patients, and Hispanic (H) patients. RESULTS: Among 2744 enrolled patients, there were 95 (3%) AA patients, 125 (5%) H patients, and 2476 (90%) W patients. Compared with W patients, more AA and H patients were diagnosed at age <45 years (P <.0001). H patients more commonly were diagnosed with grade 3 FL compared with AA and W patients (29%, 13%, and 18%, respectively; P =.019) and more commonly received rituximab plus chemotherapy as initial therapy compared with W patients (66% vs 50%; P =.036), while AA patients less commonly received anthracyclines (49% vs 64% in W patients; P =.027). H and AA patients who received rituximab plus chemotherapy were less likely than W patients to receive maintenance rituximab (27% vs 31% vs 40%, respectively; P =.031). At a median follow-up of 52 months, progression-free survival was similar between AA and W patients but was longer in H patients, and there was no difference in overall survival. CONCLUSIONS: In the largest prospective cohort to date of AA and H patients with FL in the United States, AA and H patients were younger at presentation. Although racial differences in treatment patterns for FL were noted, additional follow-up is needed to determine the impact of these differences on survival.

AB - BACKGROUND: Racial differences in follicular lymphoma (FL) in the United States have not been investigated. METHODS: The National LymphoCare Study is a multicenter, longitudinal, observational cohort study collecting data on treatment patterns and outcomes for patients with newly diagnosed FL in the United States between 2004 and 2007 without any predefined, study-specific intervention. The authors investigated differences between white (W) patients, African American (AA) patients, and Hispanic (H) patients. RESULTS: Among 2744 enrolled patients, there were 95 (3%) AA patients, 125 (5%) H patients, and 2476 (90%) W patients. Compared with W patients, more AA and H patients were diagnosed at age <45 years (P <.0001). H patients more commonly were diagnosed with grade 3 FL compared with AA and W patients (29%, 13%, and 18%, respectively; P =.019) and more commonly received rituximab plus chemotherapy as initial therapy compared with W patients (66% vs 50%; P =.036), while AA patients less commonly received anthracyclines (49% vs 64% in W patients; P =.027). H and AA patients who received rituximab plus chemotherapy were less likely than W patients to receive maintenance rituximab (27% vs 31% vs 40%, respectively; P =.031). At a median follow-up of 52 months, progression-free survival was similar between AA and W patients but was longer in H patients, and there was no difference in overall survival. CONCLUSIONS: In the largest prospective cohort to date of AA and H patients with FL in the United States, AA and H patients were younger at presentation. Although racial differences in treatment patterns for FL were noted, additional follow-up is needed to determine the impact of these differences on survival.

KW - African Americans

KW - follicular lymphoma

KW - Hispanics

KW - non-Hodgkin lymphoma

KW - racial disparities

UR - http://www.scopus.com/inward/record.url?scp=84866492718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866492718&partnerID=8YFLogxK

U2 - 10.1002/cncr.27513

DO - 10.1002/cncr.27513

M3 - Article

C2 - 22434428

AN - SCOPUS:84866492718

VL - 118

SP - 4842

EP - 4850

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 19

ER -